Payment overview · 2025
General Payments
$4,821.57
271 reported records · 20 companies
Healthcare provider profile · identity verified
Sanjeev Rao, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRIDGEPORT, CT · NPI 1548287378
Verified facts
What the public records show
CMS Open Payments records show Sanjeev Rao, MD received $4,821.57 in general payments during 2025 across 271 reported records.
ABBVIE INC. accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Otezla, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 612 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Auvelity by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 568 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 612 claims for Linzess by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $614.75 | 12.8% | 44 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $584.56 | 12.1% | 29 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $524.82 | 10.9% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $439.52 | 9.1% | 22 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $422.27 | 8.8% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $404.99 | 8.4% | 13 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $392.50 | 8.1% | 29 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $284.62 | 5.9% | 21 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $273.97 | 5.7% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $165.35 | 3.4% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.14 | 3.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.66 | 3.0% | 22 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $135.39 | 2.8% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.54 | 1.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.36 | 1.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.92 | 1.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.57 | 0.8% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $27.60 | 0.6% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $26.43 | 0.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $20.61 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,821.57 | 271 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $584.56 | 29 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $572.15 | 41 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $469.74 | 19 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $392.50 | 29 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $389.25 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $343.69 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $325.52 | 15 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $300.71 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $284.62 | 21 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $273.97 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $247.96 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $166.08 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $142.66 | 22 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $135.39 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $124.77 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $117.34 | 7 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $117.34 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $103.46 | 16 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $96.75 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $80.49 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $52.92 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.60 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.60 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.57 | 2 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $33.23 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| LITFULO Normalized: litfulo |
Drug | PFIZER INC. | $4.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 206 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 107 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 364 | exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 612 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 204 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 64 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 568 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 272 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
612 | 96 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
272 | 40 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
364 | 74 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
568 | 85 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
612 | 96 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
206 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
364 | 74 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
204 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 704 | 155 |
| Linzess | Linaclotide | 612 | 96 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 568 | 85 |
| Losartan Potassium | Losartan Potassium | 544 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 487 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 87 |
| Nifedipine Er | Nifedipine | 397 | 65 |
| Jardiance | Empagliflozin | 364 | 74 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 324 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 316 | 51 |
| Vraylar | Cariprazine Hcl | 272 | 40 |
| Metformin Hcl | Metformin Hcl | 228 | 57 |
| Lisinopril | Lisinopril | 217 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 52 |
| Montelukast Sodium | Montelukast Sodium | 212 | 34 |
| Prednisone | Prednisone | 210 | 176 |
| Caplyta | Lumateperone Tosylate | 206 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 205 | 54 |
| Ozempic | Semaglutide | 204 | 29 |
| Mirtazapine | Mirtazapine | 196 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 32 |
| Tramadol Hcl | Tramadol Hcl | 192 | 23 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 188 | 174 |
| Pioglitazone Hcl | Pioglitazone Hcl | 184 | 37 |
| Pregabalin | Pregabalin | 182 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 173 | 46 |
| Ventolin Hfa | Albuterol Sulfate | 157 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 15 |
| Tradjenta | Linagliptin | 155 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 40 |
| Gabapentin | Gabapentin | 144 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 140 | 22 |
| Naproxen | Naproxen | 138 | 26 |
| Lamotrigine | Lamotrigine | 137 | 20 |
| Glyxambi | Empagliflozin/Linagliptin | 131 | 21 |
| Ibuprofen | Ibuprofen | 128 | 71 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 122 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 117 | 26 |
| Eliquis | Apixaban | 107 | 18 |
| Vilazodone Hcl | Vilazodone Hcl | 102 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 21 |
| Celecoxib | Celecoxib | 99 | 24 |
| Furosemide | Furosemide | 97 | 21 |
| Januvia | Sitagliptin Phosphate | 97 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 15 |
| Carvedilol | Carvedilol | 94 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 24 |
| Meloxicam | Meloxicam | 86 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 83 | 18 |
| Farxiga | Dapagliflozin Propanediol | 83 | 19 |
| Atenolol | Atenolol | 77 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 14 |
| Trazodone Hcl | Trazodone Hcl | 77 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 17 |
| Fluconazole | Fluconazole | 76 | 27 |
| Mounjaro | Tirzepatide | 72 | 12 |
| Allopurinol | Allopurinol | 71 | 11 |
| Xarelto | Rivaroxaban | 71 | 11 |
| Omeprazole | Omeprazole | 69 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 18 |
| Valacyclovir | Valacyclovir Hcl | 66 | 17 |
| Rybelsus | Semaglutide | 64 | 15 |
| Doxepin Hcl | Doxepin Hcl | 63 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 12 |
| Mometasone Furoate | Mometasone Furoate | 61 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 59 | 15 |
| Metformin Hcl Er | Metformin Hcl | 59 | suppressed |
| Colchicine | Colchicine | 58 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 55 | suppressed |
| Azithromycin | Azithromycin | 52 | 51 |
| Cefdinir | Cefdinir | 52 | 50 |
| Creon | Lipase/Protease/Amylase | 47 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 15 |
| Ondansetron Odt | Ondansetron | 43 | 17 |
| Ammonium Lactate | Ammonium Lactate | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 35 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | suppressed |
| Mupirocin | Mupirocin | 37 | 12 |
| Ofloxacin | Ofloxacin | 37 | 33 |
| Finasteride | Finasteride | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Gemtesa | Vibegron | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 32 | 12 |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 32 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nyamyc | Nystatin | 25 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Sucraid | Sacrosidase | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Otezla | Apremilast | 20 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Temazepam | Temazepam | 17 | 12 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Acitretin | Acitretin | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,821.57 · 271 records | ABBVIE INC. | ABRYSVO, AREXVY, ARISTADA, Auvelity, BREZTRI, CAPLYTA, CIBINQO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, IQIRVO, JARDIANCE, LITFULO, LYBALVI, Linzess, MOUNJARO, NUCALA, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error